Clinical samples and cell lines. Leukemic DNA and cryopreserved lymphoblast samples were provided by collaborating institutions in the United States
l e t t e r s
Tumor suppressor genes on the X chromosome may skew the gender distribution of specific types of cancer 1,2 . T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy with an increased incidence in males 3 . In this study, we report the identification of inactivating mutations and deletions in the X-linked plant homeodomain finger 6 (PHF6) gene in 16% of pediatric and 38% of adult primary T-ALL samples. Notably, PHF6 mutations are almost exclusively found in T-ALL samples from male subjects. Mutational loss of PHF6 is importantly associated with leukemias driven by aberrant expression of the homeobox transcription factor oncogenes TLX1 and TLX3. Overall, these results identify PHF6 as a new X-linked tumor suppressor in T-ALL and point to a strong genetic interaction between PHF6 loss and aberrant expression of TLX transcription factors in the pathogenesis of this disease.
T-ALL is an aggressive malignancy in which multiple genetic defects collaborate in the transformation of T-cell progenitors 4, 5 . Notably, T-ALL has a threefold higher incidence in males 3 , whereas other immature hematological tumors such as precursor B-lineage ALL are equally frequent in males and females 3 .
To identify a possible X-linked tumor suppressor in T-ALL, we performed an X-chromosome-targeted mutational analysis in tumor DNA samples from 12 males with T-ALL. For each sample, we performed in-solution DNA capture of 7,674 regions encompassing 3,045,708 nucleotides corresponding to 5,215 X-chromosome exons using the Agilent Sure Select oligonucleotide capture system 6 . DNA samples enriched for X-chromosome exons were then analyzed by next-generation sequencing using the SOLiD 3 platform from Applied Biosystems. This analysis identified 66 candidate previously uncharacterized nonsynonymous single-nucleotide variants and 7 positions with high confidence calls for containing complex variants such as insertions or deletions (Fig. 1a) . Dideoxynucleotide DNA sequencing of PCR products encompassing affected exons confirmed the presence of 92% (61/66) of these single-nucleotide variants and 57% (4/7) of the more complex variants, including 2 insertions and 2 deletions (Supplementary Tables 1 and 2 ). Sequence analysis of paired DNA samples obtained at the time of clinical remission showed that most of these variants corresponded to previously unreported germline polymorphisms. However, and most notably, we also identified three somatically acquired changes corresponding to two nonsynonymous single-nucleotide substitutions (A902G T300A and A990G H330R) and a frameshift-creating insertion of five nucleotides (124_125insAGGCA, H43fs) in the PHF6 gene (Fig. 1a) .
In a complementary approach we analyzed X-chromosome array comparative genome hybridization (array-CGH) data from 246 primary T-ALL samples (179 male and 67 female) in a multicenter setting. These analyses revealed the presence of recurrent deletions in chromosomal band Xq26 in 8 out of 246 (~3%) T-ALL samples ( Table 1) . For three del(X)(q26)-positive T-ALL samples, we performed array-CGH analysis against the corresponding remission material, which showed that these Xq26 deletions were somatically acquired leukemia-associated genetic events ( Table 1) . Reanalysis of all eight del(X)(q26)-positive T-ALL samples on a custom l e t t e r s high-resolution X-chromosome oligonucleotide array (Fig. 1b,c) narrowed down the common minimally deleted region to an area of 80 kb containing the PHF6 gene. Consistently, quantitative PCR analysis confirmed loss of the PHF6 locus in the del(X)(q26)-positive cases (Fig. 1d) . The convergent findings of our X-chromosome exon mutation analysis and analysis of copy number alterations by array-CGH thus identified PHF6 as a new tumor suppressor gene mutated and deleted in T-ALL.
PHF6 encodes a plant homeodomain (PHD) factor containing four nuclear localization signals and two imperfect PHD zinc-finger domains 7 with a proposed role in controlling gene expression 7 . Notably, inactivating mutations in PHF6 cause Börjeson-ForssmanLehmann syndrome (MIM301900), a relatively uncommon type of X-linked familial syndromic mental retardation that has not been associated with increased incidence of T-ALL [7] [8] [9] . Quantitative RT-PCR analysis demonstrated ubiquitous expression of PHF6 transcripts in human tissues, with highest levels of expression in thymus, ovary and thyroid, and moderate levels of expression in spleen, testes and adipose tissue (Supplementary Fig. 1 ). Consistent with these results, PHF6 was readily detected by immunohistochemistry in mouse thymus (Supplementary Fig. 1 ). Finally, quantitative RT-PCR analysis of human thymocyte populations at different stages of development showed variable levels of PHF6 expression, with marked upregulation of PHF6 transcripts in CD4/CD8 doublepositive cells (Supplementary Fig. 1 ).
Mutational analysis of PHF6 in an extended panel of pediatric and adult T-ALL primary samples identified truncating or missense mutations in PHF6 in 38% (16/42) of adult and ~16% (14/89) of pediatric T-ALL samples ( Fig. 2a and Table 1 ). In all available cases (7/30), analysis of matched buccal and/or bone marrow remission genomic DNA confirmed the somatic origin of PHF6 mutations (4/21 frameshift mutations and 3/9 missense mutations) ( Fig. 2b and Table 1 ). Finally, no mutations in PHF6 were identified in DNA samples from B-lineage ALL (n = 62), suggesting that mutational loss of PHF6 in lymphoid tumors could be restricted to T-ALL.
Nonsense and frameshift mutations accounted for 70% (21/30) of all PHF6 mutations identified in our series and were evenly distributed throughout the gene. Missense mutations accounted for the remaining 30% (9/30) of PHF6 lesions and recurrently involved codon C215 and the second zinc-finger domain of the protein (Fig. 2a) . DNA sequence analysis of PHF6 in a panel of 15 well-characterized T-ALL cell lines (Supplementary Table 3) showed the presence of truncating mutations in PHF6 in the DND41, HPB-ALL and T-ALL1 cell lines. Protein blot analysis and immunohistochemical staining demonstrated robust expression and nuclear localization of PHF6 in PHF6 wild-type tumors and complete loss of PHF6 protein in T-ALL cell lines harboring mutations in PHF6 (Fig. 2c,d) .
PHD finger-containing proteins have been implicated in numerous cellular functions, including transcriptional regulation and in some instances as specialized reader modules that recognize the methylation status of histone lysine residues 10 . In addition, PHF6 has been reported to be phosphorylated during mitosis 11 and by the ATM and ATR kinases upon DNA damage 12 , which suggests a dynamic regulation of PHF6 during cell cycle and DNA repair. Consistent with this notion, short hairpin RNA (shRNA) knockdown of PHF6 resulted in increased levels of phosphorylated H2AX (γ-H2AX), a post-translational modification associated with the presence of DNA double-strand breaks 13 (Fig. 2e) .
Sex determination in humans is controlled by differential representation of the X and Y chromosomes, with the presence of an XY pair in males and two copies of the X chromosome in females. The presence of numerous genes in the nonautosomal region of the X chromosome could result in a genetic imbalance between male and female cells, which is compensated for by random chromosomal inactivation of one copy of the X chromosome in female cells 14 . However, allelic-expression analysis has shown that some genes can escape X-chromosome inactivation in certain tissues 1, 2, 15 . To test the possibility that PHF6 could escape X-chromosome inactivation in T-ALL cells, we performed allelic-expression analysis of a silent SNP (rs17317724) located in the 3′ UTR of PHF6 in lymphoblasts from three informative samples from females with T-ALL. In each of these samples, PHF6 was monoallelically expressed, suggesting that biallelic l e t t e r s expression of PHF6 is not commonly found in T-ALL (Fig. 3a) . Most notably, we found that PHF6 mutations are almost exclusively found in samples from males with T-ALL. PHF6 mutations were present in 32% (29/92) of males and in only ~2.5% (1/39) of females (P < 0.001; Fig. 3b and Supplementary Table 4) . Moreover, all eight PHF6 deletions identified by array-CGH analysis were found in samples from males with T-ALL, and each of the three cell lines with mutations in PHF6 were derived from males with T-ALL. 
Immunohistochemical analysis of PHF6 expression in wild-type primary T-ALL samples showed positive PHF6 immunostaining (n = 5; three males and two females), whereas cases with PHF6-truncating mutations (n = 4) (Fig. 3c) or a point mutation in C215 (C215F) were negative for PHF6 protein expression (Fig. 3c) . In contrast, primary T-ALL cells harboring a PHF6 point mutation in the PHD2 domain (T300A) were positive for PHF6 protein expression (Fig. 3c) . Overall, these results suggest that truncating mutations and point mutations in C215 impair PHF6 expression, whereas amino acid substitutions in the PHD2 domain of PHF6 may selectively impair the tumor suppressor function of this protein.
Leukemic transformation of immature thymocytes is the result of a multistep process involving numerous genetic abnormalities, which can be associated with different clinical features, including age and prognosis. Notably, PHF6 mutations were significantly more prevalent in adult T-ALL patients (16/42; 38%) than in pediatric patients (14/89; 16%) (P = 0.005; Fig. 4a ). Detailed genetic information was available for T-ALL cases treated in Dutch Childhood Oncology Group (DCOG) clinical trials (n = 65) (Supplementary Table 5 ). In this cohort, PHF6 mutations were significantly associated with the aberrant expression of TLX1 and TLX3 (P < 0.005; Fig. 4b and Supplementary Table 5), two related oncogenes activated by chromosomal translocations in T-ALL [16] [17] [18] . No significant associations were observed between PHF6 mutations and NOTCH1, FBXW7 or PTEN mutations in either pediatric (n = 65) or adult (n = 34) T-ALL cohorts (Supplementary Tables 5 and 6 ). Overall survival in PHF6 wild-type children with T-ALL treated on DCOG protocols 19 was 65% (33/51) vs. 71% (10/14) for PHF6-mutated cases (log-rank P = 0.71) (Fig. 4c) . Overall survival in PHF6 wild-type adults with T-ALL treated in the Eastern Cooperative Oncology Group ECOG-2993 clinical trial was 36% (7/12) vs. 58% (8/22) for PHF6-mutated samples (log-rank P = 0.24) (Fig. 4d) .
Overall, these results identify PHF6 as a new X-linked tumor suppressor gene and imply a specific interaction between the oncogenic programs activated by aberrant expression of TLX transcription factors and mutational loss of PHF6 in the pathogenesis of T-ALL.
MeThOds
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/. X chromosome exome capture and next-generation sequencing. Libraries of synthetic biotinylated RNA oligonucleotides (baits) targeting the X-chromosome exons were obtained from Agilent Technologies. The targeted region includes 5,217 exons for a total of 3 megabases and is designed to capture 85% of the exons on the human X chromosome. Fragment libraries using 2-4 µg of genomic DNA as starting material were prepared following the SOLiD standard library preparation protocol with some modifications, including the use of shortened adaptors and a precapture amplification for six cycles. A total of 500 ng of captured library were hybridized with the baits for 42 h, washed and eluted using the protocol provided by Agilent. The resulting captured DNA was amplified using Herculase II Fusion DNA polymerase (Agilent) for 18 cycles. Enrichment in the targeted regions was calculated by real-time PCR quantification of single exons within four X-chromosome loci (ARSF, OTC, NAP1L3 and SOX3), which showed an average enrichment of 400-to 1,200-fold for the different loci across the 12 different samples. After library quantification by real-time PCR, the amplified captured libraries were subjected to emulsion PCR and sequenced following standard SOLiD 3 protocols by depositing 10-15 million beads per sample using an eight-region mask.
Note: Supplementary information is available on the Nature Genetics website.
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A reference genome of the captured regions was created based on the March 2006 human reference sequence (hg18). To map the sequence data into this reference genome, we used the SHRiMP algorithm with its default parameters 21 . SOLiD platform employs a two-base encoding system, where a single variation in the color space solely indicates a sequencing error and two consecutive variations in the color space point to a base change in the nucleotide-space. In our analysis we included only the reads with a maximum number of two color-space mismatches that are also uniquely mapped to the reference genome. An average 90.1% of the reference genome is covered in the 12 samples, where the mean depth is 42 per base. Less restrictive filtering increases the false-positive rate of candidate genomic variants without improving the coverage to any great extent. We found 66 candidates of exonic nonsynonymous single-nucleotide variation by requiring each variation to be reported in a minimum 75% of at least three reads mapping to its position. These candidates exclude the previously reported SNPs in the human genome. Using ParMap, an algorithm specifically developed to identify small deletions and insertions (along with their nucleotide sequence) through statistical analysis of partially mapped reads 22 , we identified seven candidates of such complex variations. Validation of the next-generation sequencing results was done by Sanger sequencing of PCR amplified exons. Overall, 89% of all previously uncharacterized candidate variants were confirmed.
Microarray-based comparative genomic hybridization. Analysis of X-chromosome array-CGH data was performed in a multicenter setting.
Depending on the institution of origin, array-CGH analysis was performed using an oligonucleotide array-CGH platform 18, 23 (Agilent) or a tiling path BAC array-CGH platform 24 . To determine the exact size of the recurrent Xq26 deletions, we reanalyzed all eight del(X)(q26)-positive T-ALL cases using a custom high-resolution X-chromosome oligonucleotide array with an average resolution of 3 kb according to the manufacturer's instructions (Agilent). Slides were scanned in a 2565AA DNA microarray scanner (Agilent). Microarray images were analyzed using Feature Extraction software (Agilent), and the data were subsequently imported into array-CGH Analytics software (Agilent).
Real-time quantification of DNA copy number. Chromosome Xq26.3 deletions were confirmed with real-time quantitative DNA PCR using the Fast SYBR Green Master Mix (Applied Biosystems) and the LightCycler 480 RealTime PCR System (Roche Diagnostics) as described 25 using TIE2 as control gene. Data were analyzed using the comparative ∆∆CT method (Applied Biosystems). The primers used for the quantitative PCR analysis of the PHF6 locus are shown in Supplementary Table 7 .
PHF6 mutation analysis. PHF6 mutations were analyzed by PCR amplification of PHF6 exons 2-10 followed by direct bidirectional DNA sequencing. The primers used for PHF6 mutation detection are summarized in Supplementary Table 7 .
Protein blot and immunohistochemistry. Protein blot analysis was performed using a rabbit polyclonal antibody specific to PHF6 (1:10,000; Novus Biologicals) recognizing a C-terminal (amino acids 315-365) epitope in PHF6; a mouse monoclonal antibody (1:1,000) recognizing an N-terminal (amino acids 120-140) PHF6 epitope 26 ; an antibody specific to γ-H2AX (1:1,000; Cell Signaling Technologies) and a mouse monoclonal antibody specific to GAPD (1:1000; Santa Cruz Biotechnology) using standard procedures.
Immunohistochemistry analysis was performed as described following the standard avidin-biotin immunoperoxidase staining procedure using an N-terminal antibody to PHF6. Briefly, PHF6 immunostaining of formalinfixed paraffin-embedded tissue sections was performed after heat-induced epitope retrieval in a microwave in citrate buffer, pH 6.0. Subsequently, sections were incubated in 10% normal goat serum for 30 min, followed by primary antibody incubation (amino acids 1-94 of rabbit polyclonal antibody to PHF6; Sigma Prestige Antibodies, dilution 1:100) overnight at 4 °C. Next, slides were incubated with biotinylated immunoglobulins specific to rabbit at a 1:1000 dilution (Vector Laboratories) for 30 min, followed by avidin-biotin peroxidase complexes at a 1:25 dilution (Vector Laboratories) for 30 min. Diaminobenzidine was used as the chromogen and hematoxylin as a nuclear counterstain.
Quantitative real-time PCR. Thymocyte populations were isolated from human thymi as described before 27 . Total RNA was extracted using the Trizol method (Invitrogen) following the manufacturer's instructions. Total RNA from 20 different normal human tissues was obtained from the FirstChoice Human Total RNA Survey Panel (Applied Biosystems). Complementary DNA (cDNA) was generated with the ThermoScript RT-PCR system (Invitrogen) and analyzed by quantitative real-time PCR using the SYBR Green RT-PCR Core Reagents kit (Applied Biosystems) and the 7300 Real-Time PCR System (Applied Biosystems). PHF6 expression levels were calculated using GAPDH as a reference gene. Primers used for PHF6 expression analysis are shown in Supplementary Table 7. SNP genotyping. Genotyping of SNP rs17317724 located in the 3′ UTR region of PHF6 was performed using a TaqMan SNP Genotyping Assay (Assay ID C__34812972_10, Applied Biosystems) according to manufacturer's instructions in DNA samples from females with wild-type PHF6 T-ALL. Genotyping was confirmed by direct DNA sequencing of PCR products encompassing the 3′ UTR of PHF6. Allelic expression analysis was performed in cDNA samples from heterozygous females with T-ALL so as to evaluate monoallelic and biallelic PHF6 expression. Before cDNA synthesis, RNA samples were treated with DNase I using the DNA-free DNase Treatment kit (Applied Biosystems) to remove any traces of genomic DNA. The PHF6 3′ UTR-specific primers used for amplification of SNP rs17317724 are also summarized in Supplementary Table 7. PHF6 shRNA knockdown. We produced lentiviral particles driving the expression of a shRNA directed against PHF6 (target sequence CAGAATTTGGAGACTTTGA) using the pGIPZ Lentiviral shRNAmir vector system (V2LHS_138602, Open Biosystems) as described 28 . We infected HEK293T cells with viral supernatants generated with pGIPZ PHF6 or an empty pGIPZ control using spinoculation in the presence of polybrene. PHF6 knockdown was evaluated by protein blot analysis at 72 h as described above.
Statistical analysis.
Fisher's exact test was used to compare the frequency of PHF6 mutations between clinical and genetic groups of T-ALL. Bar graphs represent mean values ± s.e.m. Therapeutic outcome was analyzed in leukemia patients treated in DCOG trials ALL7, ALL8 and ALL9 and in ECOG trial 2993 according to overall survival. Kaplan-Meier curves were used to assess survival, and differences between groups were compared by the log-rank test.
